Latest stories on NVCR
Novocure enters clinical trial collab, supply agreement with Verastem
The Fly63 · neutralproduct/pr
Novocure: A Mispriced Cash-Generating Biotech With Upside Potential
Seeking Alpha68 · bullishanalyst
NovoCure Gains Japanese Approval for Optune Pax Pancreatic Therapy
TipRanks73 · bullishproduct/pr
Novocure receives approval for Optune Pax in Japan
The Fly67 · bullishproduct/pr
NovoCure Ltd (NVCR) files 8-K
SEC 8-K50 · neutralgeneral
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
StockTitan67 · bullishproduct/pr
Novocure to Report Third Quarter 2026 Financial Results
StockTitan50 · neutralearnings
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
NovoCure Announces Routine Board Transition After Director Retirement
TipRanks50 · neutralgeneral
NovoCure Ltd (NVCR) files 8-K
SEC 8-K50 · neutralgeneral
NovoCure’s PANOVA-4 Trial Hits Completion, Raising New Questions for Pancreatic Cancer Investors
TipRanks58 · neutralproduct/pr
Novocure Announces Upcoming Investor Events
StockTitan55 · neutralgeneral
NovoCure drops as customer information leaked in cyberattack
Seeking Alpha38 · neutralgeneral
Novocure aware of unauthorized access to some information systems
The Fly34 · bearishgeneral
NovoCure Ltd (NVCR) files 8-K
SEC 8-K50 · neutralgeneral
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
Quartz63 · neutralanalyst
NovoCure: Why I'm Fading The Q2 Earnings Rally
Seeking Alpha48 · neutralanalyst
NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)
Seeking Alpha71 · bullishearnings
NovoCure Limited 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today?
Stocktwits News67 · bullishgeneral
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?
Stocktwits News73 · bullishearnings
Novocure outlines 2026 revenue of $710M-$725M while targeting adjusted EBITDA of $0M-$15M
Seeking Alpha67 · bullishearnings
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 Outlook
Yahoo Finance73 · bullishearnings